Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 1
1991 1
1996 1
1999 1
2003 1
2011 1
2014 1
2015 3
2016 2
2017 2
2019 3
2020 1
2021 3
2022 3
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM. Bewersdorf JP, et al. Ann Hematol. 2024 Jan;103(1):105-116. doi: 10.1007/s00277-023-05552-4. Epub 2023 Dec 1. Ann Hematol. 2024. PMID: 38036712 Clinical Trial.
During dose escalation (n=13 patients), there was one dose-limiting toxicity (DLT) on dose level (DL) 1 (G5 pneumonia/bronchoalveolar hemorrhage) and two DLTs at DL 2 (G3 pharyngeal mucositis and G3 anorexia). Per the 3 + 3 dose escalation design, DL 1 (entinostat 8 …
During dose escalation (n=13 patients), there was one dose-limiting toxicity (DLT) on dose level (DL) 1 (G5 pneumonia/bronchoalveolar hemorr …
Radiobiological modeling of radiation-induced acute mucosal toxicity (oral mucositis and pharyngeal mucositis): A single-institutional study of head-and-neck carcinoma.
Singh B, Singh G, Oinam AS, Kumar V, Vashistha R, Sidhu MS, Singh M. Singh B, et al. J Cancer Res Ther. 2023 Apr;19(Supplement):S0-S1715. doi: 10.4103/jcrt.jcrt_504_21. J Cancer Res Ther. 2023. PMID: 37147947 Free article.
MATERIALS AND METHODS: Thirty H-and-N cancer patients were enrolled to model the SDR curve for oral and pharyngeal mucositis. The patients were evaluated weekly for acute radiation-induced (ARI) oral and pharyngeal mucositis toxicity, and their scoring …
MATERIALS AND METHODS: Thirty H-and-N cancer patients were enrolled to model the SDR curve for oral and pharyngeal mucositis. …
Clinical Implementation of Robust Multi-isocentric Volumetric Modulated Arc Radiotherapy for Craniospinal Irradiation.
Smyth G, Mowat S, Chia K, Robinson K, Warren-Oseni K, Welsh LC, Blasiak-Wal I, Mandeville HC. Smyth G, et al. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):211-219. doi: 10.1016/j.clon.2022.01.004. Epub 2022 Jan 19. Clin Oncol (R Coll Radiol). 2022. PMID: 35063327 Free article.
AIMS: To determine if multi-isocentric volumetric modulated arc radiotherapy for craniospinal irradiation (CSI-VMAT) can be implemented safely and accurately using robust optimisation in a commercially available treatment planning system. Our initial clinical experience is …
AIMS: To determine if multi-isocentric volumetric modulated arc radiotherapy for craniospinal irradiation (CSI-VMAT) can be implemented safe …
Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma.
Yamauchi M, Sato Y, Ishida T, Minesaki A, Shimazaki E, Kuratomi Y. Yamauchi M, et al. In Vivo. 2023 Sep-Oct;37(5):2224-2228. doi: 10.21873/invivo.13323. In Vivo. 2023. PMID: 37652522 Free PMC article.
The 1- and 3-year overall survival rates were 85.7% and 47.6%, respectively. The most common adverse events (AEs) were pharyngeal mucositis (100%), radiation dermatitis (100%), anorexia (28.6%), weight loss (28.6%), acneiform rash (28.6%), and dry mouth (28.6%). Gra …
The 1- and 3-year overall survival rates were 85.7% and 47.6%, respectively. The most common adverse events (AEs) were pharyngeal …
Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer.
Genot-Klastersky MT, Paesmans M, Ameye L, Kayumba A, Beauvois S, Dragan T, Van Gestel D, Lalami Y, Klastersky JA. Genot-Klastersky MT, et al. Support Care Cancer. 2020 Jul;28(7):3015-3022. doi: 10.1007/s00520-019-05041-3. Epub 2019 Sep 9. Support Care Cancer. 2020. PMID: 31502227
The most common and distressing acute complication of such therapies is oral/pharyngeal mucositis that may be associated with severe morbidity and can interfere with the planned administration of therapy. ...
The most common and distressing acute complication of such therapies is oral/pharyngeal mucositis that may be associated with …
Objective evaluation of nutritional status using the prognostic nutritional index during and after chemoradiotherapy in Japanese patients with head and neck cancer: a retrospective study.
Fujiwara D, Tsubaki M, Takeda T, Miura M, Nishida S, Sakaguchi K. Fujiwara D, et al. Eur J Hosp Pharm. 2021 Sep;28(5):266-270. doi: 10.1136/ejhpharm-2019-001979. Epub 2019 Aug 17. Eur J Hosp Pharm. 2021. PMID: 34426479 Free PMC article.
The median length of hospitalisation after therapy was 5 days in patients with grades 1 and 2 and 10 days in patients with grade 3 oral and pharyngeal mucositis (p<0.05). The optimal cut-off PNI value as a criterion for hospital discharge was found to be 40.4 (gr …
The median length of hospitalisation after therapy was 5 days in patients with grades 1 and 2 and 10 days in patients with grade 3 oral and …
Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity-modulated radiotherapy with concurrent chemotherapy.
Blake CL, Brown TE, Pelecanos A, Moroney LB, Helios J, Hughes BGM, Chua B, Kenny LM. Blake CL, et al. Head Neck. 2023 Feb;45(2):417-430. doi: 10.1002/hed.27249. Epub 2022 Nov 25. Head Neck. 2023. PMID: 36433667
RESULTS: The threshold for patients needing 50% of estimated requirements via EN increased from week 3 to 4 for grade 2 oral/pharyngeal mucositis, dysgeusia, thick saliva and nausea, and for grade 3 dysphagia. Patients with grade 2-3 dysphagia had a reduced risk of …
RESULTS: The threshold for patients needing 50% of estimated requirements via EN increased from week 3 to 4 for grade 2 oral/pharyngeal …
Clinical Outcomes of Intensity-modulated Carbon-ion Radiotherapy for Bone and Soft Tissue Tumors.
Takakusagi Y, Koge H, Kano K, Shima S, Tsuchida K, Mizoguchi N, Yoshida D, Kamada T, Katoh H. Takakusagi Y, et al. Anticancer Res. 2023 Jun;43(6):2777-2781. doi: 10.21873/anticanres.16446. Anticancer Res. 2023. PMID: 37247930
We retrospectively analyzed the clinical results of IMCT for BSTs and investigated treatment efficacy and toxicity. ...Acute toxicity of Grade 2 or higher was seen in 2 patients with Grade 2 pharyngeal mucositis. Late toxicities of Grade 2 or higher included …
We retrospectively analyzed the clinical results of IMCT for BSTs and investigated treatment efficacy and toxicity. ...Acute toxicity …
Mucositis: current management and investigations.
Garden AS. Garden AS. Semin Radiat Oncol. 2003 Jul;13(3):267-73. doi: 10.1016/S1053-4296(03)00028-6. Semin Radiat Oncol. 2003. PMID: 12903015
Oral and pharyngeal mucositis present significant management problems for patients undergoing radiation for head and neck cancers. ...
Oral and pharyngeal mucositis present significant management problems for patients undergoing radiation for head and neck canc …
Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Ota Y, Kodaira T, Fujii H, Shimokawa M, Yokota T, Nakashima T, Monden N, Homma A, Ueda S, Akimoto T. Ota Y, et al. Int J Clin Oncol. 2022 Nov;27(11):1675-1683. doi: 10.1007/s10147-022-02228-3. Epub 2022 Aug 24. Int J Clin Oncol. 2022. PMID: 36001247
Here, we conducted a prospective multi-institutional observational study to evaluate clinical outcomes of BRT in patients with LA-SCCHN. METHODS: We analyzed real-world data of all patients who underwent BRT from 2013 to 2016. ...N stage, T stage, and comorbidity were sign …
Here, we conducted a prospective multi-institutional observational study to evaluate clinical outcomes of BRT in patients with LA-SCC …
27 results